NCT03920605 (HBV) is a NA clinical trial of Tenofovir Disoproxil Fumarate in Hepatitis B, sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

Who is sponsoring NCT03920605?

NCT03920605 is sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

What drugs are being tested in NCT03920605?

Interventions in NCT03920605: Tenofovir Disoproxil Fumarate, Peginterferon Alfa-2a, Peginterferon Alfa-2b.

What condition does NCT03920605 study?

NCT03920605 studies Hepatitis B, Liver Fibrosis.

Is NCT03920605 still recruiting?

NCT03920605 is currently status unknown. Last updated 22 May 2019.

Last reviewed 2019-05-22 · How we verify

NCT03920605: HBV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis

Status unknown NA Last updated 22 May 2019

What this trial tests

NA trial testing Tenofovir Disoproxil Fumarate in Hepatitis B in 100 participants. Status unknown.

Timeline

1 February 2019

Primary endpoint
30 October 2021

31 December 2021

Quick facts

Lead sponsor	Third Affiliated Hospital, Sun Yat-Sen University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 February 2019
Primary completion	30 October 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Tenofovir Disoproxil Fumarate — full drug profile →
Peginterferon Alfa-2a (PEGINTERFERON ALFA-2A) — full drug profile →
Peginterferon Alfa-2b — full drug profile →

Conditions studied

Hepatitis B — all drugs for Hepatitis B →
Liver Fibrosis — all drugs for Liver Fibrosis →

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Who can join

Adults 15 to 55, any sex, with Hepatitis B or Liver Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate treatment of peginterferon alfa 2a/2b in anti-virus treatment experienced patients with HBV related liver fibrosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tenofovir Disoproxil Fumarate

Trials testing the same drug.

NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06586983 — Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia · recruiting
NCT06356662 — Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease · Phase 1 · recruiting
NCT04862975 — Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana · completed
NCT06573190 — Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B · completed

Other recruiting trials for Hepatitis B

Currently open trials in the same condition.

NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
NCT07168356 — A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease · Phase 1 · recruiting
NCT06947356 — Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads · NA · recruiting
NCT06537414 — A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living Wit · Phase 2 · active not recruiting
NCT06623071 — Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384 · recruiting

Other Third Affiliated Hospital, Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07409259 — PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure · EARLY_PHASE1 · active not recruiting
NCT07281664 — Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hep · NA · not yet recruiting
NCT07338552 — Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China · NA · not yet recruiting
NCT07354997 — Establishing a Virtual Health Community Management Model for Pre-Diabetes Patients · NA · completed
NCT07253233 — Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03920605 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Third Affiliated Hospital, Sun Yat-Sen University
Last refreshed: 22 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03920605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing